Menopause and Perimenopause: Symptoms, HRT, NHS Treatment and Long-Term Health Guide

Menopause is a natural biological transition marking the end of a woman’s menstrual cycles, confirmed after 12 consecutive months without a period. In the UK, the average age of natural menopause is 51, with perimenopause — the transitional phase — typically beginning 4–8 years earlier. Approximately 13 million women in the UK are currently peri or postmenopausal. Menopause is not an illness, but its hormonal changes can cause significant symptoms affecting quality of life, long-term bone health, and cardiovascular health.

Perimenopause vs Menopause: What’s the Difference?

  • Perimenopause — the transition period leading up to menopause; periods become irregular; oestrogen levels fluctuate and decline; symptoms often begin; typically lasts 4–8 years but can be up to 10 years
  • Menopause — defined as 12 consecutive months without a period; average age 51 in the UK
  • Postmenopause — the years after menopause; symptoms may continue for years; long-term health risks (bone density loss, cardiovascular risk) become more prominent
  • Premature ovarian insufficiency (POI) — menopause before age 40; affects approximately 1 in 100 women; requires early HRT for bone and cardiovascular protection
  • Early menopause — between ages 40–45; affects approximately 5% of women

Menopause Symptoms

Symptoms vary enormously between women — some experience minimal disruption while others face severe, debilitating effects. Up to 25% of women have severe symptoms:

Vasomotor Symptoms

  • Hot flushes — sudden intense heat, often with sweating; affect up to 80% of women; can last 1–5 minutes; may persist for 7–10 years
  • Night sweats — disrupting sleep significantly

Psychological Symptoms

  • Anxiety, low mood, irritability, and mood swings
  • Brain fog — difficulty concentrating, poor memory, word-finding problems
  • Fatigue and poor sleep
  • Reduced confidence and motivation

Genitourinary Symptoms (GSM — Genitourinary Syndrome of Menopause)

  • Vaginal dryness, thinning, and discomfort during sex (dyspareunia)
  • Recurrent urinary tract infections
  • Bladder urgency, frequency, and mild urinary incontinence

Other Symptoms

  • Joint and muscle aches (musculoskeletal symptoms — often overlooked)
  • Skin and hair changes — thinning hair, dry skin
  • Palpitations
  • Headaches
  • Weight changes — particularly increased abdominal fat
  • Reduced libido

Diagnosis in the UK

NICE guideline NG23 (2015, updated 2019) states that:

  • Menopause should be diagnosed clinically in women over 45 with typical symptoms — blood tests are not routinely needed
  • FSH (follicle-stimulating hormone) can be checked in women aged 40–45 or those on hormonal contraception — though a single test may be unreliable due to fluctuation in perimenopause
  • In women under 40 with suspected POI, FSH should be checked twice, 4–6 weeks apart

Many women are told by GPs that their symptoms are depression or anxiety when they are in perimenopause — particularly in their early-to-mid 40s when periods may still be regular. If you suspect perimenopause, ask your GP specifically to consider this diagnosis.

HRT: Hormone Replacement Therapy

HRT is the most effective treatment for menopausal symptoms. The major shift in UK guidance came in 2019 when NICE and the British Menopause Society (BMS) updated their recommendations, recognising that the widely-feared risks from the 2002 WHI study were significantly overstated for most women.

What NICE Now Says About HRT Safety

For most healthy women under 60 or within 10 years of menopause:

  • Breast cancer risk: Combined (oestrogen + progestogen) HRT carries a small increased risk — approximately 4 extra cases per 1,000 women over 5 years. Oestrogen-only HRT (for women who have had a hysterectomy) carries minimal breast cancer risk. The risk from HRT is similar to or less than that from drinking 1–2 units of alcohol daily or being overweight.
  • Cardiovascular disease: Starting HRT within 10 years of menopause or before age 60 does not increase cardiovascular risk — and may be cardioprotective
  • Blood clots (VTE): Oral HRT carries a small increased VTE risk; transdermal HRT (patches, gels, sprays) does not increase VTE risk — an important distinction for women with higher clot risk
  • Stroke: Transdermal HRT does not increase stroke risk; oral oestrogen carries a small increased risk

Types of HRT Available on NHS

  • Oestrogen — patches (Evorel, Estradot), gels (Oestrogel, Sandrena), sprays (Lenzetto), tablets (Elleste Solo), implants
  • Progestogen — required for women with a uterus to protect the endometrium; available as tablets (norethisterone, dydrogesterone), Mirena IUS (levonorgestrel), or as part of combined preparations
  • Combined HRT — cyclical (for perimenopausal women still having periods) or continuous (for postmenopausal women)
  • Testosterone — available on NHS for women with low libido; transdermal gel (Testogel used off-label or specialist products)
  • Vaginal oestrogen — local treatment for GSM; very minimal systemic absorption; safe long-term for almost all women including most breast cancer survivors

The Great Progestogen Debate: Body-Identical Progesterone

Body-identical (micronised) progesterone (Utrogestan) has a better safety profile than synthetic progestogens — with lower breast cancer risk, no negative effects on mood, and no increase in VTE risk. NICE and BMS now recommend it as the preferred progestogen in HRT for women who need it. Ask your GP specifically for micronised progesterone if you are concerned about breast cancer risk from HRT.

Non-Hormonal Options for Menopause Symptoms

  • Cognitive Behavioural Therapy (CBT) — NICE-recommended for hot flushes, night sweats, anxiety, and low mood; available through NHS Talking Therapies
  • Clonidine — prescription medication for hot flushes; modest efficacy
  • SSRIs/SNRIs (venlafaxine, escitalopram) — reduce hot flush frequency; useful when HRT is contraindicated (e.g. hormone-sensitive breast cancer)
  • Gabapentin — used off-label for hot flushes
  • Fezolinetant (Veoza) — a new non-hormonal NK3 receptor antagonist approved by MHRA in 2023 for vasomotor symptoms; NICE assessment ongoing
  • Vaginal lubricants and moisturisers — for GSM; available without prescription

Long-Term Health Risks After Menopause

Osteoporosis

Oestrogen is critical for maintaining bone density. In the first 5 years post-menopause, women lose up to 10% of bone mass. HRT is the most effective treatment for preventing postmenopausal bone loss. Women with early menopause or POI should take HRT until at least age 51 for bone protection. See our osteoporosis guide.

Cardiovascular Disease

Before menopause, oestrogen is cardioprotective. After menopause, women’s cardiovascular risk increases rapidly and exceeds men’s by age 65–70. Cardiovascular disease is the leading cause of death in postmenopausal women. HRT started before age 60 or within 10 years of menopause may reduce cardiovascular risk — the “timing hypothesis”. See our hypertension guide and cholesterol guide.

UK Support and Resources

  • British Menopause Society (BMS) — thebms.org.uk | NHS-endorsed specialist guidance and healthcare professional finder
  • Menopause Matters — menopausematters.co.uk | Comprehensive UK menopause information
  • Henpicked: Menopause in the Workplace — henpicked.net | Workplace menopause guidance and resources
  • Daisy Network — daisynetwork.org | Charity for premature ovarian insufficiency (POI)
  • Wellbeing of Women — wellbeingofwomen.org.uk | Menopause research and advocacy
  • NHS Menopause Support — nhs.uk/conditions/menopause

What Major Health Sites Often Miss About Menopause

1. Transdermal HRT Has No VTE or Stroke Risk — A Critical Safety Difference

Many global health sites present HRT risks without distinguishing between oral and transdermal preparations. UK-specific NICE guidance (and BMS guidance) clearly states that transdermal oestrogen (patches, gels, sprays) does not increase the risk of VTE (blood clots) or stroke — unlike oral oestrogen tablets. This distinction is fundamental to prescribing safe HRT and is embedded in NHS clinical practice, but rarely emphasised by non-UK health sites.

2. Body-Identical Progesterone vs Synthetic Progestogens

Utrogestan (micronised progesterone) has a significantly better safety profile than older synthetic progestogens, including lower breast cancer risk. The 2019 BMS guidelines specifically recommend it as the preferred progestogen. Yet many GPs in the UK still default to norethisterone — patients can and should ask for micronised progesterone if they are concerned.

3. Menopause in the Workplace: A UK Legal Dimension

In the UK, severe menopausal symptoms may constitute a disability under the Equality Act 2010 — giving women legal rights to reasonable adjustments in the workplace. The EHRC and ACAS have issued guidance on this. This is a UK-specific legal context not addressed by international health sites, but increasingly important as 25% of menopausal women consider leaving work due to symptoms.

Related Health Guides on YourHealthXpert